BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8242797)

  • 1. Activation of the complement system by the capsule of Cryptococcus neoformans.
    Kozel TR
    Curr Top Med Mycol; 1993; 5():1-26. PubMed ID: 8242797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opsonization and phagocytosis of Cryptococcus neoformans.
    Kozel TR
    Arch Med Res; 1993; 24(3):211-8. PubMed ID: 8298269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.
    Kozel TR; Wilson MA; Murphy JW
    Infect Immun; 1991 Sep; 59(9):3101-10. PubMed ID: 1831795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance.
    Zaragoza O; Casadevall A
    Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
    Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
    Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
    Kozel TR; Pfrommer GS
    Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement.
    Verbrugh HA; Peterson PK; Nguyen BY; Sisson SP; Kim Y
    J Immunol; 1982 Oct; 129(4):1681-7. PubMed ID: 7108223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection.
    Diamond RD; May JE; Kane MA; Frank MM; Bennett JE
    J Immunol; 1974 Jun; 112(6):2260-70. PubMed ID: 4596700
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions.
    Zaragoza O; Taborda CP; Casadevall A
    Eur J Immunol; 2003 Jul; 33(7):1957-67. PubMed ID: 12884862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Infect Immun; 1988 Nov; 56(11):2794-800. PubMed ID: 3049374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
    Laxalt KA; Kozel TR
    Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans.
    Cross CE; Collins HL; Bancroft GJ
    Immunology; 1997 Jun; 91(2):289-96. PubMed ID: 9227330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium tuberculosis and the complement system.
    Schlesinger LS
    Trends Microbiol; 1998 Feb; 6(2):47-9; discussion 49-50. PubMed ID: 9507637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways.
    Mershon-Shier KL; Vasuthasawat A; Takahashi K; Morrison SL; Beenhouwer DO
    Mol Immunol; 2011 Sep; 48(15-16):2009-18. PubMed ID: 21723612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Physiopathology of meningoencephalitis caused by Cryptococcus neoformans].
    Neuville S; Dromer F; Chrétien F; Gray F; Lortholary O
    Ann Med Interne (Paris); 2002 Sep; 153(5):323-8. PubMed ID: 12442078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
    Kozel TR; Gotschlich EC
    J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of humoral factors in host resistance to the Bacteroides fragilis group.
    Bjornson AB
    Rev Infect Dis; 1990; 12 Suppl 2():S161-8. PubMed ID: 2406868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subversion of complement activation at the bacterial surface promotes serum resistance and opsonophagocytosis of Francisella tularensis.
    Ben Nasr A; Klimpel GR
    J Leukoc Biol; 2008 Jul; 84(1):77-85. PubMed ID: 18430786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the capsule in phagocytosis of Cryptococcus neoformans.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Rev Infect Dis; 1988; 10 Suppl 2():S436-9. PubMed ID: 3055212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation, binding, and processing of complement component 3 (C3) by Blastomyces dermatitidis.
    Zhang MX; Klein B
    Infect Immun; 1997 May; 65(5):1849-55. PubMed ID: 9125571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.